20/20 Biolabs Inc (AIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Assets | ||
| Current Assets | ||
| Cash & Cash Equivalents | 1,026 | 1,784 |
| Receivables | 200 | 135 |
| Inventories | 116 | 47 |
| TOTAL | $1,471 | $2,034 |
| Non-Current Assets | ||
| PPE Net | 57 | 117 |
| Intangibles | 1,079 | 1,272 |
| Other Non-Current Assets | 1,531 | 162 |
| TOTAL | $2,666 | $1,550 |
| Total Assets | $4,137 | $3,584 |
| Liabilities | ||
| Current Liabilities | ||
| Short Term Debt | 75 | N/A |
| Accounts payable and accrued liabilities | 869 | 372 |
| Accrued Expenses | 786 | 347 |
| Other current liabilities | 143 | N/A |
| TOTAL | $2,463 | $1,355 |
| Non-Current Liabilities | ||
| Deferred Revenues | 415 | 471 |
| Other Non-Current Liabilities | 1,652 | 674 |
| TOTAL | $1,693 | $724 |
| Total Liabilities | $4,157 | $2,079 |
| Shareholders' Equity | ||
| Common Shares | 54 | 48 |
| Retained earnings | -33,247 | -29,508 |
| Other shareholders' equity | 0 | -29 |
| TOTAL | $-19 | $1,506 |
| Total Liabilities And Equity | $4,137 | $3,584 |